NasdaqGS:TLRYPharmaceuticals
Tilray (NasdaqGS:TLRY) Valuation After Schedule III Shift and Tilray Medical USA Launch
Tilray Brands (NasdaqGS:TLRY) just tied its next chapter to a big policy shift, with President Trump moving marijuana to Schedule III and the company launching Tilray Medical USA to pursue U.S. medical cannabis opportunities.
See our latest analysis for Tilray Brands.
That policy pivot has not stopped volatility, with a 7 day share price return of minus 21.2 percent and year to date share price return of minus 30.5 percent. The 3 year total shareholder return of minus 60.7 percent shows...